Mesenchymal stem cells: The challenge of a good therapeutic product;Cellules souches mésenchymateuses: Production à usage clinique et contraintes sécuritaires

Medecine/Sciences

Volumn 27, Issue 3, 2011, Pages 297-302

  Sensebé, Luc ^a,b   Bourin, Philippe ^a,b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b Institut National de la Sant é et de la Recherche Medicale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CULTURE MEDIUM; CULTURE TECHNIQUE; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; STANDARD;

CELL CULTURE TECHNIQUES; CULTURE MEDIA; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS;

EID: 79955047001     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2011273297     Document Type: Article

References (38)

1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society far cellular therapy position statement. Cytotherapy 2006; 8: 315-7. (Pubitemid 44269669)
2. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-13.
3. Sensebé L, Bourin P. Producing MSC according GMP: process and controls. Biomed Mater Eng 2008; 18: 173-7.
4. Baxter MA, Wynn RF, Jowitt SN, et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-82. (Pubitemid 39172200)
5. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008; 129: 163-73.
6. Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-301. (Pubitemid 44464698)
7. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-34. (Pubitemid 39014578)
8. Gronthos S, Zannettino ACW, Hay SJ, et al. Molecular and cellular characterisation of highly purified stromal cells derived from human bone marrow. J Cell Set 2003; 116: 1827-35. (Pubitemid 36582169)
9. Quirici N, Soligo D, Bossolasco P, et al. Isolation of bone marrow mesenchymal stem cells by antinerve growth factor receptor antibodies. Exp Hematol 2002; 30: 783-91. (Pubitemid 34835685)
10. Deschaseaux F, Charbord P. Human marrow stromal precursors are alpha 1 integrin subunitpositive. J Cell Physiol 2000; 184: 319-25. (Pubitemid 30625494)
11. Koç ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and cultured-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy J Clin Oncol 2000; 18: 307-16. (Pubitemid 30056419)
12. Colter DC, Sekiya I, Prackop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001; 98: 7841-5. (Pubitemid 32642648)
13. Sekiya I, Larson BJ, Smith JR, et al. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002; 20: 530-41. (Pubitemid 35463066)
14. Banfi A, Muraglia A, Dozin B, et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp Hematol 2000; 28: 707-15. (Pubitemid 30398528)
15. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113: 1161-6. (Pubitemid 30229533)
16. Ng F, Boucher S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008; 112: 295-307.
17. Muller I, Kordowich S, Holzwarth C, et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006; 8: 437-44. (Pubitemid 44596996)
18. Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB serum and thrombinactivated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007; 25: 1270-8. (Pubitemid 46684887)
19. Chase LG, Lakshmipathy U, Solchaga LA, et al. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2010; 1: 8.
20. Tarte K, Gaillard J, Lataillade JJ, et al. Société française de greffe de moelle et thérapie cellulaire. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115: 1549-53.
21. Godara P, McFarland CD, Nordon RE. Design of bioreactors for mesenchymal stem cell tissue engineering. J Chem Technol Biotechnol 2010; 83: 408-20.
22. Serakinci N, Guldberg P, Burns JS, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004; 23: 5095-8. (Pubitemid 38938744)
23. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-9. (Pubitemid 40524580)
24. Rosland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009; 69: 5331-9.
25. Garcia S, Martin MC, de la Fuente R, et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010; 316: 1648-50.
26. Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track. Cancer Res 2010; 70: 6393-6.
27. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1963; 37: 614-36.
28. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-40. (Pubitemid 47312822)
29. Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PloS Biol 2008; 12: 2853-68.
30. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-44. (Pubitemid 37409409)
31. Houghton JM, Li H, Fan X, et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cell Dev 2010; 19: 1153-66.
32. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PloS One 2008; 3: 1-12.
33. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576-8.
34. Bischof O, Dejean A, Pineau P. Une revue de la sénescence cellulaire : ami ou ennemi de la promotion tumorale? Med Sci (Paris) 2009; 25: 153-60.
35. Charbard P, Casteilla L. La biologie des cellules souches mésenchymateuses d'origine humaine. Med Sci (Paris) 2011; 27: 261-8.
36. Lazennec G. Les cellules souches mésenchymateuses: armes ou dangers pour le traitement des cancers? Med Sci (Paris) 2011; 27: 285-8.
37. Jorgensen C, Deschaseaux F, Planat-Benard V, Gabison E. Les cellules souches mésenchymateuses: actualités thérapeutiques. Med Sci (Paris) 2011; 27: 275-84.
38. Vinatier C, Bordenave L, Guicheux J, Amédée J. Les cellules souches en ingénierie des tissus ostéoarticulaires et vasculaires. Med Sci (Paris) 2011; 27: 289-96.